Pfizer Inc. (NYSE: PFE) – Pharmaceuticals

NYSE: PFE | Market Cap: ~$150 billion USD | Sector: Healthcare/Pharmaceuticals

Company Overview

Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for developing and manufacturing innovative medicines and vaccines. Founded over 175 years ago, Pfizer has been responsible for some of the most important medical breakthroughs in history, including the COVID-19 vaccine (Comirnaty) developed with BioNTech.

Key Facts

Founded: 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York
Headquarters: New York City, New York, USA
NYSE Listing: 1942
CEO: Albert Bourla, DVM, PhD (since 2019)
Employees: 83,000+ globally
Operations: 125+ countries
R&D sites: Major facilities in US, UK, Belgium, China
Market Position: Top 5 global pharmaceutical company by revenue
Dividend Aristocrat candidate: 14+ consecutive years of dividend increases (pre-COVID)

Recent Corporate Transformation

Post-COVID Transition (2023-2024)

COVID revenue decline: Comirnaty and Paxlovid sales falling from $57B (2022) to ~$10B (2024)
Portfolio restructuring: Divesting non-core assets, focusing on high-growth areas
Cost reduction: $4B+ cost-cutting program (2023-2024)
Strategic acquisitions: Seagen ($43B, 2023) – transformative oncology deal
Pipeline focus: Oncology, immunology, rare diseases, vaccines

Business Segments

Revenue by Therapeutic Area (FY2023)

Segment	Revenue	% of Total	Key Products
Oncology	$12.7B	22%	Ibrance, Xtandi, Inlyta, Lorbrena
COVID Products	$12.5B	21%	Comirnaty, Paxlovid
Primary Care	$10.8B	18%	Eliquis, Vyndaqel, Nurtec ODT
Specialty Care	$10.2B	17%	Xeljanz, Enbrel (international)
Hospital	$7.9B	13%	Prevnar family, biosimilars
Other	$4.6B	8%	Consumer health (divested), other

Total Revenue: $58.5 billion (2023)

Major Product Portfolio

1. Oncology (~22% of revenue)

IBRANCE® (palbociclib)

Indication: Breast cancer (HR+/HER2-)
Mechanism: CDK4/6 inhibitor
Sales: $5.0 billion (2023)
Status: Facing generic competition (US patent expired 2023)
Challenge: Revenue declining 30-40% annually due to generics

XTANDI® (enzalutamide)

Indication: Prostate cancer
Mechanism: Androgen receptor inhibitor
Sales: $3.7 billion (2023, Pfizer share)
Partnership: Co-marketed with Astellas (Pfizer gets ~50% of profits)
Growth: Expanding to earlier treatment lines

INLYTA® (axitinib)

Indication: Renal cell carcinoma (kidney cancer)
Mechanism: VEGFR inhibitor
Sales: $1.1 billion (2023)
Combinations: Used with checkpoint inhibitors (Keytruda, Opdivo)

LORBRENA® (lorlatinib)

Indication: ALK+ non-small cell lung cancer
Mechanism: ALK/ROS1 inhibitor
Sales: $600 million (2023)
Growth: 40%+ annually, moving to first-line treatment

BRAFTOVI® + MEKTOVI® (encorafenib + binimetinib)

Indication: BRAF-mutant melanoma, colorectal cancer
Sales: $500 million (2023)

Seagen Acquisition (2023, $43B)

ADCETRIS® (brentuximab vedotin)

Indication: Hodgkin lymphoma, systemic anaplastic large cell lymphoma
Mechanism: Antibody-drug conjugate (ADC) targeting CD30
Sales: $1.4 billion (2023)

PADCEV® (enfortumab vedotin)

Indication: Urothelial cancer (bladder cancer)
Mechanism: ADC targeting Nectin-4
Sales: $900 million (2023)
Growth: 80%+ annually, expanding to earlier treatment lines
Blockbuster potential: $5B+ peak sales projected

TIVDAK® (tisotumab vedotin)

Indication: Cervical cancer
Mechanism: ADC targeting tissue factor
Sales: $100 million (2023)
Early stage: Significant growth potential

ADC Pipeline

10+ ADC programs in development
Platform technology for future oncology drugs
Seagen acquisition rationale: ADC expertise and pipeline

2. COVID-19 Products (~21% of revenue, declining)

COMIRNATY® (COVID-19 vaccine)

Partnership: Developed with BioNTech (Germany)
Technology: mRNA vaccine
Sales: $11.2 billion (2023), down from $37.8B (2022)
Market share: ~70% of US COVID vaccine market
Revenue split: Pfizer books all revenue, pays BioNTech for their share
Future outlook: $3-5B annual revenue (endemic/seasonal market)

PAXLOVID® (nirmatrelvir/ritonavir)

Indication: COVID-19 treatment (oral antiviral)
Mechanism: Protease inhibitor
Sales: $1.3 billion (2023), down from $18.9B (2022)
Government contracts: Revenue dependent on government purchases
Future outlook: $1-2B annual revenue

COVID Revenue Cliff

Peak (2022): $56.7 billion combined
2023: $12.5 billion (78% decline)
2024 estimate: $8-10 billion
2025+ estimate: $5-8 billion (endemic market)
Challenge: Replacing $50B+ in lost revenue

3. Primary Care (~18% of revenue)

ELIQUIS® (apixaban)

Indication: Atrial fibrillation, deep vein thrombosis, pulmonary embolism
Mechanism: Factor Xa inhibitor (anticoagulant)
Sales: $6.0 billion (2023, Pfizer share)
Partnership: Co-marketed with Bristol Myers Squibb (Pfizer gets ~50%)
Market position: #1 oral anticoagulant globally
Patent expiry: US 2026 (generics expected 2028 after pediatric exclusivity)
Peak sales: Pfizer’s largest non-COVID product

VYNDAQEL® family (tafamidis)

Indication: Transthyretin amyloid cardiomyopathy (ATTR-CM)
Mechanism: TTR stabilizer
Sales: $3.7 billion (2023)
Growth: 60%+ annually
Pricing: $225,000/year (high-cost specialty drug)
Market expansion: Increasing diagnosis of rare disease
Blockbuster: Potential $5-7B peak sales

NURTEC® ODT (rimegepant)

Indication: Migraine (acute treatment and prevention)
Mechanism: CGRP receptor antagonist (oral)
Sales: $1.0 billion (2023)
Acquisition: Biohaven Pharmaceuticals (2022, $11.6B)
Growth: 30%+ annually
Competition: Abbvie’s Ubrelvy, Eli Lilly’s Emgality

4. Specialty Care (~17% of revenue)

XELJANZ® (tofacitinib)

Indications: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis
Mechanism: JAK inhibitor (oral)
Sales: $2.4 billion (2023)
Challenge: FDA black box warning (cardiovascular, cancer risks)
Competition: Abbvie’s Rinvoq (newer JAK inhibitor gaining share)
Outlook: Declining revenue due to safety concerns and competition

ENBREL® (etanercept) – International only

Indications: Rheumatoid arthritis, psoriasis, psoriatic arthritis
Mechanism: TNF-alpha inhibitor
Sales: $2.0 billion (2023, ex-US only)
Note: Amgen markets Enbrel in US/Canada; Pfizer has rest of world rights
Biosimilar competition: Revenue declining due to biosimilars in Europe

LITFULO® (ritlecitinib)

Indication: Alopecia areata (severe hair loss)
Mechanism: JAK3/TEC inhibitor
Approval: 2023 (first oral treatment for alopecia)
Sales: Early stage, ramping up
Potential: $1B+ peak sales

5. Hospital (~13% of revenue)

PREVNAR® family (pneumococcal vaccines)

PREVNAR 20® (20-valent)

Indication: Pneumococcal disease prevention (adults and children)
Sales: $6.3 billion (2023)
Market position: #1 pneumococcal vaccine
Competition: Merck’s Vaxneuvance (15-valent), Capvaxive (21-valent, approved 2024)
Growth: Transitioning from Prevnar 13 to Prevnar 20

Biosimilars

RUXIENCE®: Rituxan biosimilar (cancer, autoimmune)
ZIRABEV®: Avastin biosimilar (cancer)
TRAZIMERA®: Herceptin biosimilar (breast cancer)
NYVEPRIA®: Neulasta biosimilar (chemotherapy support)
Sales: $1.5 billion combined (2023)
Strategy: Competing with originator biologics at lower prices

Hospital Injectables

Antibiotics (Zithromax, Sulperazon)
Sterile injectables
Anesthetics

6. Divested/Declining Products

Consumer Health (Divested 2022)

Brands: Advil, Centrum, ChapStick, Preparation H, Robitussin
Buyer: GSK Consumer Healthcare (now Haleon)
Rationale: Focus on prescription pharmaceuticals

LIPITOR® (atorvastatin)

Former blockbuster cholesterol drug
Generic since 2011
Peak sales: $13B annually (2006)
Legacy product, minimal current revenue

VIAGRA® (sildenafil)

Erectile dysfunction treatment
Generic since 2017
Peak sales: $2B annually
Iconic brand, but no longer significant revenue

Research & Development Pipeline

R&D Investment

Annual R&D spend: $10.7 billion (2023) – 18% of revenue
Pipeline: 100+ programs in clinical development
Focus areas: Oncology (40% of pipeline), immunology, rare diseases, vaccines
Strategy: Internal R&D + strategic acquisitions + partnerships

Late-Stage Pipeline (Phase III)

Oncology

Elranatamab: BCMA-targeted bispecific antibody for multiple myeloma
Sasanlimab: PD-1 inhibitor (checkpoint inhibitor) for various cancers
Padcev combinations: Expanding bladder cancer indications (first-line treatment)
ADC pipeline: 10+ antibody-drug conjugates in development

Immunology

Etrasimod: S1P receptor modulator for ulcerative colitis (approved 2023 as VELSIPITY®)
Ritlecitinib: Expanding to vitiligo, Crohn’s disease, ulcerative colitis
Abrocitinib: JAK1 inhibitor for atopic dermatitis (approved 2021 as CIBINQO®)

Rare Diseases

Giroctocogene fitelparvovec: Gene therapy for hemophilia B
Fordadistrogene movaparvovec: Gene therapy for Duchenne muscular dystrophy
Vyndaqel expansion: Additional amyloidosis indications

Vaccines

RSV vaccine: ABRYSVO® (approved 2023) for respiratory syncytial virus
Lyme disease vaccine: Phase III trials with Valneva
Group B Streptococcus vaccine: Maternal immunization
Combination vaccines: Pneumococcal + flu, COVID + flu

Cardiovascular

Danuglipron: Oral GLP-1 agonist for obesity and diabetes (competing with Ozempic/Wegovy)
Lotiglipron: Alternative oral GLP-1 program

Key Pipeline Milestones (2024-2026)

2024: Elranatamab approval decision (multiple myeloma)
2024: Danuglipron Phase III data (obesity)
2025: Padcev first-line bladder cancer approval
2025: Gene therapy approvals (hemophilia B, DMD)
2026: Multiple ADC approvals

Strategic Acquisitions

Major Deals (2019-2024)

Company	Year	Price	Rationale
Seagen	2023	$43B	ADC platform, oncology pipeline
Biohaven	2022	$11.6B	Nurtec (migraine), CGRP platform
Arena Pharma	2021	$6.7B	Etrasimod (immunology)
Trillium Therapeutics	2021	$2.3B	CD47 antibodies (oncology)
Array BioPharma	2019	$11.4B	Braftovi/Mektovi (melanoma)

Acquisition Strategy

Bolt-on deals: Acquiring late-stage assets and platforms
Focus areas: Oncology, immunology, rare diseases
Risk: High prices paid, integration challenges
Rationale: Faster than internal R&D, filling pipeline gaps

Geographic Revenue Mix

Revenue by Region (FY2023)

Region	Revenue	% of Total
United States	$32.0B	55%
Europe	$13.2B	23%
Emerging Markets	$7.6B	13%
Japan	$3.2B	5%
Rest of World	$2.5B	4%

Competitive Landscape

Major Competitors

Oncology

Roche: Herceptin, Avastin, Tecentriq
Merck: Keytruda (dominant PD-1 inhibitor)
Bristol Myers Squibb: Opdivo, Yervoy, Revlimid
AstraZeneca: Tagrisso, Imfinzi, Lynparza
Johnson & Johnson: Darzalex, Erleada, Imbruvica

Immunology

AbbVie: Humira, Skyrizi, Rinvoq (dominant JAK inhibitor)
Johnson & Johnson: Stelara, Tremfya, Simponi
Amgen: Enbrel, Otezla
Eli Lilly: Taltz, Olumiant

Vaccines

Merck: Gardasil (HPV), pneumococcal vaccines
GSK: Shingrix, meningitis vaccines
Sanofi: Flu vaccines, pediatric vaccines
Moderna: mRNA platform (COVID, RSV, flu)

Cardiovascular

Bristol Myers Squibb: Eliquis (co-marketed with Pfizer)
Johnson & Johnson/Bayer: Xarelto
Boehringer Ingelheim: Pradaxa

Pfizer’s Competitive Position

Strengths

✅ Scale: Global manufacturing, distribution, regulatory expertise
✅ Vaccine leadership: Prevnar, Comirnaty, ABRYSVO
✅ ADC platform: Seagen acquisition provides cutting-edge oncology technology
✅ Financial resources: Strong balance sheet for acquisitions, R&D
✅ Diversified portfolio: Multiple therapeutic areas

Weaknesses

❌ Patent cliffs: Ibrance (2023), Eliquis (2026) losing exclusivity
❌ COVID revenue collapse: $50B+ revenue loss to replace
❌ Pipeline gaps: Limited late-stage blockbusters (pre-Seagen)
❌ Immunology weakness: Xeljanz losing to Rinvoq
❌ Acquisition integration: Seagen, Biohaven execution risk

Financial Performance

Revenue Trends

Year	Revenue	Growth	Notes
2019	$51.8B	-4%	Pre-COVID baseline
2020	$41.9B	-19%	Upjohn spin-off (Viatris)
2021	$81.3B	+94%	COVID vaccine launch
2022	$100.3B	+23%	COVID peak
2023	$58.5B	-42%	COVID decline, Seagen added
2024E	$59-62B	+2-6%	Stabilization

Profitability Metrics (FY2023)

Gross margin: 59.1%
Operating margin: 17.2%
Net profit margin: 37.6% (includes one-time gains)
Adjusted net profit margin: 22.8%
Return on equity (ROE): 18.3%
EBITDA: $16.2 billion

Earnings Per Share

Reported EPS: $3.86 (2023)
Adjusted EPS: $1.84 (2023) – excluding COVID, restructuring, acquisition costs
2024 guidance: $2.45-$2.65 adjusted EPS
2025+ outlook: Mid-single-digit EPS growth

Dividend History

Annual dividend: $1.68 per share (2024)
Dividend yield: 6.0-6.5% (historically high due to stock price decline)
Payout ratio: ~90% of adjusted earnings (elevated)
Consecutive increases: 14 years (2009-2023, paused 2024 due to COVID transition)
Dividend safety: Sustainable, but growth paused during restructuring
Quarterly payments: March, June, September, December

Balance Sheet (FY2023)

Total assets: $226 billion
Cash and investments: $10.8 billion
Total debt: $61.9 billion
Net debt: $51.1 billion
Debt/EBITDA: 3.2x (elevated due to Seagen acquisition)
Credit rating: AA (S&P), Aa1 (Moody’s) – strong investment grade

Cash Flow (FY2023)

Operating cash flow: $12.0 billion
Free cash flow: $9.6 billion
Capex: $2.4 billion (~4% of revenue)
Cash conversion: 44% of net income (low due to one-time items)

Capital Allocation (FY2023)

Dividends: $9.5 billion
Share buybacks: $0 (suspended during COVID transition)
M&A: $43 billion (Seagen acquisition)
R&D: $10.7 billion
Debt paydown: Priority after Seagen acquisition

Investment Thesis

Bull Case 🐂

High Dividend Yield

6%+ yield: Among highest in large-cap pharma
Sustainable: Strong cash flow supports dividend
Income investors: Attractive for dividend-focused portfolios
Yield on cost: Long-term holders benefit from historical dividend growth

Seagen Acquisition Upside

ADC platform: Cutting-edge oncology technology
Padcev growth: 80%+ annual growth, $5B+ peak sales potential
Pipeline value: 10+ ADC programs in development
Synergies: Pfizer’s global scale + Seagen’s innovation
Accretion: Deal expected to be accretive to EPS by 2025

Vyndaqel Growth Driver

$3.7B sales (2023): 60%+ annual growth
Rare disease expansion: Increasing ATTR-CM diagnosis
Peak sales potential: $5-7 billion
Long patent life: Exclusivity through 2030s
High margins: Specialty drug pricing ($225K/year)

Vaccine Franchise

Prevnar 20: $6.3B sales, market leader
ABRYSVO (RSV): New vaccine, $1B+ potential
Combination vaccines: COVID + flu, pneumococcal + flu in development
Endemic COVID: $3-5B annual revenue (seasonal boosters)
Lyme disease vaccine: Phase III, large unmet need

Pipeline Potential

Elranatamab: Multiple myeloma bispecific, blockbuster potential
Danuglipron: Oral GLP-1 for obesity (competing with Ozempic/Wegovy)
Gene therapies: Hemophilia B, Duchenne muscular dystrophy
ADC pipeline: 10+ programs, multiple approvals expected 2025-2027

Valuation Attractive

Low P/E: Trading at 10-12x earnings (vs 15-20x for peers)
Discount to intrinsic value: Market undervaluing pipeline
Turnaround story: Post-COVID restructuring creating value
Contrarian opportunity: Negative sentiment creates buying opportunity

Cost Reduction Program

$4B savings: 2023-2024 cost-cutting initiative
Margin expansion: Operating leverage as revenue stabilizes
Efficiency gains: Streamlining operations post-COVID

Bear Case 🐻

Risks and Challenges

Patent Cliffs

Ibrance (2023): $5B revenue declining 30-40% annually (generics launched)
Eliquis (2026): $6B revenue at risk (US patent expiry, generics 2028)
Xeljanz: Declining due to safety concerns and competition
Enbrel (ex-US): Biosimilar erosion in Europe
Revenue headwind: $10B+ annual revenue facing generic/biosimilar competition

COVID Revenue Collapse

$50B+ revenue loss: From $57B (2022) to $8-10B (2024)
Difficult to replace: Few drugs generate $10B+ annually
Margin pressure: COVID products had high margins
Investor disappointment: Market expected better post-COVID transition

Pipeline Execution Risk

Danuglipron uncertainty: Oral GLP-1 program facing tolerability issues
Late-stage failures: Clinical trials can fail (high risk in pharma)
Competitive threats: Crowded oncology, immunology markets
Regulatory delays: FDA approvals unpredictable

Seagen Integration Challenges

$43B price tag: High valuation, execution risk
Debt burden: Increased leverage (3.2x debt/EBITDA)
Cultural integration: Combining large pharma + biotech cultures
Synergy realization: May take longer than expected
Overpayment risk: Did Pfizer pay too much?

Dividend Sustainability Concerns

High payout ratio: ~90% of adjusted earnings
Dividend growth paused: No increase in 2024 (first time in 14 years)
Debt paydown priority: Capital allocation focused on deleveraging
Cut risk: If earnings disappoint, dividend could be reduced

Competitive Pressures

Oncology: Merck’s Keytruda dominance, intense competition
Immunology: AbbVie’s Rinvoq taking share from Xeljanz
Vaccines: Merck’s pneumococcal vaccines (Capvaxive) competing with Prevnar
GLP-1 race: Eli Lilly, Novo Nordisk far ahead in obesity market

Regulatory & Pricing Pressure

Inflation Reduction Act: Medicare drug price negotiation
Eliquis targeted: Selected for 2026 Medicare negotiation
International price controls: Europe, Japan, emerging markets
Rebate pressure: PBMs demanding higher rebates

Management Credibility

Overpromising: 2023 guidance missed, revised down multiple times
Acquisition strategy: High prices paid, integration challenges
COVID windfall spent: $100B+ COVID revenue not fully reinvested in pipeline
Investor trust: Stock down 40%+ from 2021 peak

Valuation Metrics

Current Trading Multiples (indicative)

P/E Ratio: 10-12x (trailing)
Forward P/E: 9-11x
Price-to-Sales: 2.5-3.0x
Price-to-Book: 1.8-2.2x
EV/EBITDA: 9-11x
Dividend Yield: 6.0-6.5%

Comparison to Peers

Company	P/E	Div Yield	Market Cap	Key Strengths
Pfizer	10x	6.5%	$150B	High yield, Seagen ADCs, vaccines
Johnson & J	16x	3.1%	$380B	Diversification, dividend aristocrat
Merck	18x	2.8%	$280B	Keytruda dominance, vaccines
AbbVie	15x	3.5%	$320B	Immunology leadership, high yield
Eli Lilly	55x	0.7%	$750B	GLP-1 dominance (Mounjaro, Zepbound)
Bristol Myers	12x	4.5%	$100B	Oncology, Eliquis, high yield

Observation: Pfizer trades at significant discount to peers, reflecting patent cliff concerns, COVID transition challenges, and execution risk

Key Catalysts to Monitor

Near-Term (2026)

Quarterly earnings: Revenue stabilization, margin trends, guidance
Elranatamab approval: FDA decision on multiple myeloma bispecific
Danuglipron Phase III data: Oral GLP-1 obesity trial results
Seagen integration: Synergy realization, Padcev growth
Dividend decision: Will Pfizer resume dividend growth?

Medium-Term (2027-2028)

Eliquis patent expiry: Generic launch impact (2028)
Padcev first-line approval: Bladder cancer expansion
Gene therapy approvals: Hemophilia B, DMD
ADC pipeline approvals: Multiple oncology drugs
Debt paydown: Deleveraging progress post-Seagen

Long-Term (2029+)

Pipeline maturation: Late-stage assets becoming blockbusters
Post-patent cliff recovery: New products replacing Ibrance, Eliquis revenue
Combination vaccines: COVID + flu, pneumococcal + flu launches
M&A opportunities: Additional bolt-on acquisitions

How to Invest in Pfizer

Direct Stock Purchase

NYSE: PFE – New York Stock Exchange
Available through US and international brokers
Dividend Reinvestment Plan (DRIP) available
Highly liquid – easy to buy/sell

ETF Exposure

Health Care Select Sector SPDR (XLV) – ~5% PFE weighting
iShares U.S. Healthcare ETF (IYH) – ~4% PFE weighting
Vanguard Health Care ETF (VHT) – ~3% PFE weighting
SPDR S&P Dividend ETF (SDY) – High dividend yield exposure
Vanguard High Dividend Yield ETF (VYM) – Dividend focus

Options Strategies

Covered calls: Generate income on stock holdings
Cash-secured puts: Acquire shares at lower prices
Dividend capture: Buy before ex-dividend date

Analyst Consensus (Indicative)

Ratings Distribution

Buy: 40% of analysts
Hold: 55% of analysts
Sell: 5% of analysts

Price Target Range

Bull case: $35-40 USD
Base case: $30-33 USD
Bear case: $24-27 USD

Note: Analyst opinions vary widely based on pipeline execution assumptions, Seagen integration success, and Eliquis generic impact

Tax Considerations (US Investors)

Dividends

Qualified dividends: Taxed at long-term capital gains rates (0%, 15%, or 20%)
Holding period: Must hold stock 60+ days around ex-dividend date
Tax-advantaged accounts: IRA, 401(k) dividends grow tax-deferred
High yield benefit: 6%+ yield attractive for taxable accounts

Capital Gains

Long-term: Held 12+ months, taxed at 0%, 15%, or 20%
Short-term: Held less than 12 months, taxed as ordinary income
Tax-loss harvesting: Selling at loss to offset gains (if stock declines)

International Investors

Withholding tax: 30% US tax on dividends (reduced by tax treaty)
Australian investors: 15% withholding under US-Australia tax treaty
Foreign tax credit: Can claim credit in home country

ESG Considerations

Environmental

Carbon neutrality goal: Net-zero emissions by 2040
Renewable energy: 100% renewable electricity by 2030
Water stewardship: Reducing water usage in manufacturing
Sustainable packaging: Recyclable materials
Pharmaceutical waste: Proper disposal programs

Social

Access to medicines: Tiered pricing for developing countries
COVID vaccine equity: 2 billion+ doses to low-income countries (at cost)
Clinical trial diversity: Increasing underrepresented populations
Employee health: Comprehensive benefits, mental health support
Community engagement: $100M+ annual charitable giving

Governance

Independent board (11 of 12 directors independent)
Separate CEO and Chairman roles
Executive compensation tied to long-term performance
Transparent financial reporting
Strong regulatory compliance programs

ESG Controversies

Drug pricing (high US prices vs international)
Opioid litigation (settled for $75M in 2022)
COVID vaccine profits (criticism of high margins)
Executive compensation ($33M CEO pay in 2022)

ESG Ratings: Generally strong scores, but drug pricing remains concern

Related Terms

Antibody-drug conjugate (ADC) – Targeted cancer therapy combining antibody + chemotherapy
Biosimilar – Generic version of biologic drug
Patent cliff – Revenue loss when drug patents expire
Blockbuster drug – Drug with $1B+ annual sales
mRNA vaccine – Messenger RNA technology (Comirnaty)
CDK4/6 inhibitor – Cancer drug class (Ibrance)
Factor Xa inhibitor – Anticoagulant class (Eliquis)
JAK inhibitor – Immunology drug class (Xeljanz)
GLP-1 agonist – Obesity/diabetes drug class (danuglipron in development)
Pneumococcal vaccine – Prevents bacterial pneumonia (Prevnar)

Disclaimer: This information is for educational purposes only and does not constitute financial or medical advice. Pfizer stock carries risks including patent expiries, pipeline execution failures, acquisition integration challenges, dividend sustainability concerns, competitive pressures, and regulatory/pricing headwinds. DYOR before making investment decisions. Past performance is not indicative of future results. Consult with financial advisors regarding investment decisions and healthcare professionals regarding medical products.

Official Website: www.pfizer.com

Investor Relations: investors.pfizer.com

NYSE Listing: www.nyse.com (Code: PFE)

SEC Filings: www.sec.gov (Search: Pfizer Inc.)

Related Topics: Pfizer, NYSE:PFE, Pharmaceutical Stocks, COVID-19 Vaccine, Comirnaty, Paxlovid, Antibody-Drug Conjugates, Seagen Acquisition, Oncology Drugs, Eliquis, Ibrance, Vyndaqel, Prevnar, Dividend Stocks, High Yield Stocks, Value Investing, Patent Cliff, Biosimilars, Drug Pricing, Healthcare Stocks, mRNA Technology, Vaccine Development

Uninformed Investors